Translational Research in Oncology
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1997-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.bcirg.org
Clinical Trials
13
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
- Conditions
- Anal Squamous Cell CarcinomaColorectal NeoplasmsCastrate Resistant Prostate CancerNeuroendocrine Carcinoma of ProstateGastroenteropancreatic Neuroendocrine NeoplasmSoft Tissue SarcomaMalignant Pleural MesotheliomaSmall Cell Lung Carcinoma
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Translational Research in Oncology
- Registration Number
- NCT05582031
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Procedure: Loco-regional therapy
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 496
- Registration Number
- NCT04777851
- Locations
- 🇺🇸
UCLA Santa Monica Hematology Oncology, Santa Monica, California, United States
🇧🇪UCL SAINT LUC - UC Louvain, Brussels, Belgium
🇧🇪Antwerp University Hospital, Edegem, Belgium
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 19
- Registration Number
- NCT04261218
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦British Columbia Cancer Vancouver, Vancouver, British Columbia, Canada
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT03004534
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Valley Breast Care and Women's Health Center, Los Angeles, California, United States
🇺🇸Torrance Memorial Physician Network, Cancer Care Associates, Redondo Beach, California, United States
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 34
- Registration Number
- NCT02900560
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
- Prev
- 1
- 2
- Next